000862746 001__ 862746
000862746 005__ 20220930130211.0
000862746 0247_ $$2doi$$a10.1038/s41598-019-41993-6
000862746 0247_ $$2Handle$$a2128/22182
000862746 0247_ $$2pmid$$apmid:30952881
000862746 0247_ $$2WOS$$aWOS:000463482800054
000862746 0247_ $$2altmetric$$aaltmetric:58931090
000862746 037__ $$aFZJ-2019-02988
000862746 082__ $$a600
000862746 1001_ $$0P:(DE-Juel1)164354$$aElfgen, Anne$$b0$$ufzj
000862746 245__ $$aMetabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
000862746 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2019
000862746 3367_ $$2DRIVER$$aarticle
000862746 3367_ $$2DataCite$$aOutput Types/Journal article
000862746 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1583736742_29854
000862746 3367_ $$2BibTeX$$aARTICLE
000862746 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000862746 3367_ $$00$$2EndNote$$aJournal Article
000862746 520__ $$aAlzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. Aggregation of the amyloid-β peptide (Aβ) plays an important role in the disease, with Aβ oligomers representing the most toxic species. Previously, we have developed the Aβ oligomer eliminating therapeutic compound RD2 consisting solely of D-enantiomeric amino acid residues. RD2 has been described to have an oral bioavailability of more than 75% and to improve cognition in transgenic Alzheimer’s disease mouse models after oral administration. In the present study, we further examined the stability of RD2 in simulated gastrointestinal fluids, blood plasma and liver microsomes. In addition, we have examined whether RD2 is a substrate for the human D-amino acid oxidase (hDAAO). Furthermore, metabolite profiles of RD2 incubated in human, rodent and non-rodent liver microsomes were compared across species to search for human-specific metabolites that might possibly constitute a threat when applying the compound in humans. RD2 was remarkably resistant against metabolization in all investigated media and not converted by hDAAO. Moreover, RD2 did not influence the activity of any of the tested enzymes. In conclusion, the high stability and the absence of relevant human-specific metabolites support RD2 to be safe for oral administration in humans.
000862746 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000862746 588__ $$aDataset connected to CrossRef
000862746 7001_ $$0P:(DE-Juel1)142389$$aHupert, Michelle$$b1$$ufzj
000862746 7001_ $$0P:(DE-Juel1)165763$$aBochinsky, Kevin$$b2$$ufzj
000862746 7001_ $$0P:(DE-Juel1)131709$$aTusche, Markus$$b3
000862746 7001_ $$0P:(DE-Juel1)168323$$aGonzález de San Román Martin, Estibaliz$$b4
000862746 7001_ $$0P:(DE-Juel1)171922$$aGering, Ian$$b5$$ufzj
000862746 7001_ $$00000-0002-2338-2561$$aSacchi, Silvia$$b6
000862746 7001_ $$00000-0003-1733-7243$$aPollegioni, Loredano$$b7
000862746 7001_ $$0P:(DE-Juel1)162356$$aHuesgen, Pitter F.$$b8
000862746 7001_ $$0P:(DE-Juel1)132001$$aHartmann, Rudolf$$b9
000862746 7001_ $$0P:(DE-Juel1)133853$$aSantiago-Schübel, Beatrix$$b10$$ufzj
000862746 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b11$$eCorresponding author$$ufzj
000862746 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b12$$eCorresponding author
000862746 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-019-41993-6$$gVol. 9, no. 1, p. 5715$$n1$$p5715$$tScientific reports$$v9$$x2045-2322$$y2019
000862746 8564_ $$uhttps://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf
000862746 8564_ $$uhttps://juser.fz-juelich.de/record/862746/files/16003723690008973348INVOIC2676139755001.pdf?subformat=pdfa$$xpdfa
000862746 8564_ $$uhttps://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf$$yOpenAccess
000862746 8564_ $$uhttps://juser.fz-juelich.de/record/862746/files/Metabolic%20resistance%20of%20the%20D-peptide%20RD2%20developed%20for%20direct%20elimination%20of%20amyloid-%CE%B2%20oligomers.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000862746 8767_ $$82676139755$$92019-03-22$$d2019-03-26$$eAPC$$jZahlung erfolgt$$pSREP-18-20538B$$zFZJ-2019-02113
000862746 909CO $$ooai:juser.fz-juelich.de:862746$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164354$$aForschungszentrum Jülich$$b0$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)142389$$aForschungszentrum Jülich$$b1$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165763$$aForschungszentrum Jülich$$b2$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131709$$aForschungszentrum Jülich$$b3$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171922$$aForschungszentrum Jülich$$b5$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162356$$aForschungszentrum Jülich$$b8$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132001$$aForschungszentrum Jülich$$b9$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133853$$aForschungszentrum Jülich$$b10$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b11$$kFZJ
000862746 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b12$$kFZJ
000862746 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000862746 9141_ $$y2019
000862746 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000862746 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000862746 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000862746 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000862746 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000862746 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2017
000862746 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000862746 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000862746 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000862746 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000862746 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000862746 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000862746 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000862746 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000862746 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000862746 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000862746 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000862746 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000862746 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000862746 920__ $$lyes
000862746 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie$$x0
000862746 9201_ $$0I:(DE-Juel1)ZEA-3-20090406$$kZEA-3$$lAnalytik$$x1
000862746 9801_ $$aAPC
000862746 9801_ $$aFullTexts
000862746 980__ $$ajournal
000862746 980__ $$aVDB
000862746 980__ $$aI:(DE-Juel1)ICS-6-20110106
000862746 980__ $$aI:(DE-Juel1)ZEA-3-20090406
000862746 980__ $$aAPC
000862746 980__ $$aUNRESTRICTED
000862746 981__ $$aI:(DE-Juel1)IBI-7-20200312